Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.1945 DKK | +2.91% | -18.96% | -54.77% |
Valuation
Fiscal Period: December | 2023 |
---|---|
Capitalization 1 | 439.9 |
Enterprise Value (EV) 1 | 465.9 |
P/E ratio | -18.9 x |
Yield | - |
Capitalization / Revenue | - |
EV / Revenue | - |
EV / EBITDA | -18.6 x |
EV / FCF | -71,69,903 x |
FCF Yield | -0% |
Price to Book | 11.3 x |
Nbr of stocks (in thousands) | 10,22,964 |
Reference price 2 | 0.4300 |
Announcement Date | 20/03/24 |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2022 | 2023 |
---|---|---|
Net sales | - | - |
EBITDA 1 | -11.02 | -25.01 |
EBIT 1 | -11.28 | -25.29 |
Operating Margin | - | - |
Earnings before Tax (EBT) 1 | -11.3 | -26.84 |
Net income 1 | -9.444 | -24.61 |
Net margin | - | - |
EPS 2 | -0.0100 | -0.0228 |
Free Cash Flow | - | -64.98 |
FCF margin | - | - |
FCF Conversion (EBITDA) | - | - |
FCF Conversion (Net income) | - | - |
Dividend per Share | - | - |
Announcement Date | 20/03/24 | 20/03/24 |
Balance Sheet Analysis
Fiscal Period: December | 2022 | 2023 |
---|---|---|
Net Debt 1 | - | 26 |
Net Cash position 1 | 2.25 | - |
Leverage (Debt/EBITDA) | - | -1.039 x |
Free Cash Flow | - | -65 |
ROE (net income / shareholders' equity) | - | -85.1% |
ROA (Net income/ Total Assets) | - | -30.7% |
Assets 1 | - | 80.05 |
Book Value Per Share 2 | 0.0200 | 0.0400 |
Cash Flow per Share 2 | 0 | 0 |
Capex | - | 0.07 |
Capex / Sales | - | - |
Announcement Date | 20/03/24 | 20/03/24 |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
1st Jan change | Capi. | |
---|---|---|
-54.77% | 27.91M | |
+21.17% | 79.58B | |
+67.35% | 18.68B | |
+9.61% | 17.17B | |
+10.85% | 14.54B | |
+3.43% | 13.02B | |
+8.26% | 12.08B | |
+9.60% | 11.23B | |
+42.47% | 10.55B | |
-1.08% | 9.82B |
- Stock Market
- Equities
- PEG A Stock
- Financials Pharma Equity Group A/S